We have studied a kindred with three siblings with isolated hypogonadotropic hypogonadism caused by compound heterozygote mutations in the GnRH receptor gene. The disorder was transmitted as an autosomal recessive trait. The R262Q mutation in intracellular loop 3 of the receptor was associated with a mutation in the third transmembrane domain of the receptor, A129D, that has never been described before. This A129D mutation results in a complete loss of function, indicated by the lack of inositol triphosphate (TP3) 3 production by transfected Chinese hamster ovary (CHO) cells after GnRH stimulation. The two brothers had microphallus and bilateral cryptorchidism and were referred for lack of puberty, whereas their sister had primary amenorrhea and a complete lack of puberty. Their basal gonadotropin concentrations were below the reference range, and their endogenous LH secretory patterns were abnormal, with a low-normal frequency of small pulses or no apparent LH pulse. Pulsatile GnRH administration (10 g/pulse every 90 min for 40 h) resulted in increased mean LH without any significant changes in testosterone levels in the two brothers, whereas the LH secretory profile of their sister remained apulsatile. Larger pulses of exogenous GnRH (20 g every 90 min for 24 h) caused the sister to produce recognizable low amplitude LH pulses. The concentrations of free ␣-subunit significantly increased in all patients during the pulsatile GnRH administration. Thus, these hypogonadal patients are partially resistant to pulsatile GnRH administration, suggesting that they should be treated with gonadotropins to induce spermatogenesis or ovulation rather than with pulsatile GnRH. (J Clin Endocrinol Metab 84: 990 -996, 1999) 
were abnormal, with a low-normal frequency of small pulses or no apparent LH pulse. Pulsatile GnRH administration (10 g/pulse every 90 min for 40 h) resulted in increased mean LH without any significant changes in testosterone levels in the two brothers, whereas the LH secretory profile of their sister remained apulsatile. Larger pulses of exogenous GnRH (20 g every 90 min for 24 h) caused the sister to produce recognizable low amplitude LH pulses. The concentrations of free ␣-subunit significantly increased in all patients during the pulsatile GnRH administration. Thus, these hypogonadal patients are partially resistant to pulsatile GnRH administration, suggesting that they should be treated with gonadotropins to induce spermatogenesis or ovulation rather than with pulsatile GnRH. (J Clin Endocrinol Metab 84: 990 -996, 1999) C ONGENITAL hypogonadotropic hypogonadism affects mostly men and is rarely diagnosed before the onset of puberty unless it is associated with other signs or symptoms (anosmia or hyposmia, midline defect, cryptorchidism, color blindness, adrenal insufficiency) or when it is familial. The genes responsible have been identified in X-linked Kallmann syndrome (1, 2) and in adrenal hypoplasia congenita (3, 4) . Mutation in the GnRH gene has been reported in the hpg/hpg mouse (5) but not yet described in humans. Rare familial cases of hypogonadic patients with mutations in the GnRH receptor (GnRHR) gene have been reported recently (6 -8) . The phenotype of these patients seems to vary from partial hypogonadotropic deficiency, with significant levels of gonadotropins (LH, FSH) and gonadal steroids (6) , to complete hypogonadism (8) . Most cases respond to an acute pharmacological GnRH test (100 g).
This report describes a family with three siblings suffering from isolated hypogonadotropic hypogonadism caused by compound heterozygous mutations in the GnRHR gene. All the affected subjects gave an incomplete and variable response of gonadotropin secretion to iv pulsatile GnRH administration, suggesting that mutations in the GnRHR gene are responsible for a variable degree of resistance to GnRH.
Subjects and Methods Patients
The family is described in Fig. 1 . The two brothers (II1 and II2) were referred for evaluation of sexual infantilism at ages 22 and 20, respectively. They had had microphallus and bilateral cryptorchidism. Patient II1 underwent right orchidectomy at age 5. Physical examination revealed the absence of facial hair and sparse pubic hair, and both patients had a testicular vol of 3 mL or less. Their body mass indexes were 32.8 and 23.3 kg/m 2 , and both brothers had bilateral gynecomastia. The sister (II3) had primary amenorrhea and complete impuberism at age 17; her breast development was Tanner stage 1.
All the siblings had a normal karyotype and normal olfaction, and no abnormality of the hypothalamus and pituitary area was visible on magnetic resonance imaging. Hormonal evaluation (Table 1) established the diagnosis of isolated hypogonadotropic hypogonadism. The two brothers were treated with oral testosterone undecanoate (Pantestone, 40 mg, t.i.d.; Organon, Puteaux, France), whereas their sister was given estrogen-and progestin-replacement therapy.
The father (I1) had normal puberty, potency, libido, and testosterone levels ( Table 1) . The mother (I2) had a normal puberty at age 14, had irregular menses, and underwent hysterectomy at age 43. There was no indication of parental consanguinity. Written informed consent for genetic and clinical studies was obtained from all the subjects.
Methods

In vitro studies
Preparation of genomic DNA and DNA sequencing EMBL/GenBank data libraries under accession numbers Z99760, Z99761, and Z99995. Products were purified on Microcon-30 columns (AMICON, Beverly, MA) and sequenced directly using the AmpliTaq dye Terminator Cycle Sequencing kit and an ABI PRISM 377 DNA sequencer (Perkin-Elmer Corp., Roissy, France). The creation or the loss of restriction sites by each of the two mutations was used to confirm the presence of the mutations and to identify family members as carriers of the mutated alleles. PCR products were digested with appropriate enzymes, according to the recommendations of the manufacturers. Digested fragments were separated by electrophoresis on agarose or polyacrylamide gels, depending on their predicted size.
Construction of wild-type and mutant GnRHR complementary DNA (cDNA) expression vectors
The full-length, wild-type GnRHR cDNA was synthesized by RT of GnRHR messenger RNA extracted from a normal pituitary gland (9) and cloned into PGEM-T easy vector (Promega Corp., Charbonnières, France). PCR products from the genomic DNA-containing mutations were cloned into the PGEM-T easy vector, and mutant cDNAs were constructed by exchanging the wild-type DNA segment with the mutated one. Both wild-type and mutated cDNAs were subcloned into pmol/LSG-CAT/Amp eukaryotic expression vector (Pharmacia Biotech, Orsay, France). The entire sequences of the cloned receptors were verified; they were identical to that of the published GnRHR, except for a synonymous A975T substitution and the expected mutations in the mutant clones.
Functional studies of the GnRHR in Chinese hamster ovary cells
CHO-K1 cells were cultured in six-well plates at 9.10 4 cells per well, in Ham-F2 containing 100 g/mL gentalline (Sigma Chemical Co., Saint Quentin Fallavier, France) and 8% newborn calf serum at 37 C. Monolayer cultures (60 -70% confluence) were transiently transfected with either the wild-type or the mutant human GnRHR cDNA cloned into pmol/LSG using lipofectamine reagent (Gibco BRL, Life Technologies, Gaithersburg, MD). Briefly, purified DNA (1.2-4.8 g) was diluted in opti-MEM solution (Gibco BRL), and the mixture was combined with Lipofectamine (24 g in opti-MEM). Cells were incubated with the complexes for 5 h at 37 C in a CO 2 incubator. The medium was replaced with fresh complete growth medium, and the cultures were maintained for 60 h to allow synthesis of the receptors before binding and functional assays. All assays were performed on at least three independent experiments, and values are means of duplicate determinations. Total RNA was extracted from the transfected cells (10) using RNA-PLUS (Bioprobe Systems, Montreuil, France), and contaminating DNA was eliminated by digestion with ribonuclease-free deoxyribonuclease I (Gibco BRL). Expression of wild-type and mutant GnRHR genes was studied by dot-blot hybridization using 32 P-cDNA GnRHR as probe (9) . 
Receptor binding assays
Inositol phosphate (IP) production
Transfected CHO-K1 cells were incubated for 48 h, to ensure receptor gene expression, and then labeled overnight with myo- [2- 3 H]inositol (6 Ci/mL; Amersham, Les Ulis, France) in an inositol-free (RPMI, Gibco BRL, Life Technologies) medium containing 20 mmol/L LiCl. Cells were washed twice with Hank's medium, containing 0.1% BSA and 20 mmol/L LiCl, and incubated for 1 h at 37 C in the same solution with or without 10 Ϫ7 mol/L GnRH. Reactions were stopped with ice-cold perchloric acid (5% final concentration). Phosphoinositides (IPs) were extracted and separated by anion-exchange resin (12) , and the incorpored radioactivity was measured in duplicate samples.
In vivo studies Protocol
Baseline hormone concentrations were measured 16 and 25 days after the withdrawal of androgen or estrogen and progestin replacement therapy. The patterns of spontaneous LH secretion of the father and the three children were then assessed. A catheter was placed in a forearm vein of each patient, and 4-mL samples of blood were taken every 10 min, for 5-8 h, starting at 0800 h. The samples were collected in EDTA tubes and centrifuged, and the plasma was stored at Ϫ20 C until assayed.
Pulsatile GnRH was given using a closed iv system (Zyklomat pulse, Lutrelef 3.2 mg, Ferring SA, Gentilly, France). GnRH pulses were given every 90 min. The dose was 10 g/pulse for 40 h for all the children. In patient II3, a dose of 20 g/pulse was subsequently administered for 24 h.
The patterns of GnRH-induced LH and free ␣-subunit secretion were evaluated by measuring the hormones in the 10-min plasma samples taken for a 6 -8 h period during pulsatile GnRH administration. Plasma steroid (testosterone, 17␤ estradiol), FSH, and inhibin concentrations were measured before and after pulsatile GnRH administration.
The gonadotropin (LH, FSH) response to GnRH was tested by iv injection of 100 g GnRH (Roussel Lab, Paris, France) before and after the pulsatile GnRH administration. Blood samples were taken immediately before, and 30 and 60 min after GnRH injection.
Assays
LH concentrations were determined using an immunoradiometric assay (IRMA) ( 125 I-hLH Coatria; BioMerieux, Marcy-l'Etoile, France). The between-assay coefficient of variation (CV) was 5.2% when the mean LH was less than 7 IU/L. The within-assay CV was less than 4. , with a between-assay CV of less than 10.5% and a within-assay CV of less than 6.5%. The cross-reactivity of LH and FSH in the ␣-subunit assay was less than 0.1%. All samples from individual subjects were run in duplicate in the same assay. FSH was determined by an IRMA ( 125 I-human FSH Coatria, BioMerieux). The between-assay CV was less than 4%; the within-assay CV was 2.8%. The FSH concentration was expressed in terms of International Standard for FSH immunoassay International Reference preparation 78/549. The normal range was 1.2-11 IU/L in men, and 1.3-11.1 IU/L in early follicular phase. RIAs were used to measure testosterone: Dina-testok, Sorin Biomedica, Saluggia, Italy (within-assay CV ϭ 9%, between-assay CV ϭ 10%, detection limit ϭ 0.18 nmol/L, normal range in men: 9.7-28.4 nmol/L) and estradiol: Estradiol-2, Sorin Diagnostics, Antony, France (within-assay ϭ 4.2%, between-assay ϭ 4.9%, detection limit ϭ 18 pmol/L, normal range in early follicular phase: 70 -220 pmol/L). Inhibin B was measured by an enzyme-linked immunosorbent assay (Serotec, Oxford, UK). Inhibin A had a 1% cross-reactivity in this assay. Intraassay precision was 7.4% at 44 pg/mL and 4.2% at 225 pg/mL. The normal range is 70 -330 pg/mL in men and 10 -300 pg/mL in the early follicular phase.
LH pulse analysis
LH pulse analysis was performed using Cluster analysis (13) with method number 7, which calculates the sd as a power function of the LH concentrations, based on series of duplicates. We selected the optimal parameter for LH male data (J. D. Veldhuis, Correspondence of all users of Cluster analysis, 24 October 1988). These parameters are reported to give minimal false positive and false negative error rates (Ͻ5%). The half-life of immunoreactive LH was estimated using the Expfit program (version 1.6) (V. Guardabasso, P. J. Munson, D. Rodbard), applied to the downstroke of every significant pulse identified by the Cluster analysis algorithm. The Expfit program was run using one exponential term for each downstroke, which allowed us to calculate the rate constant (R). The half-life was determined as a Napierian logarithm of 2/R. The apparent half-life of LH in each patient was the mean of values for all identified LH pulses.
Results
In vitro studies
DNA sequencing and haplotyping of the GnRHR gene. Two germline mutations were found in all three siblings with hypogonadotropic hypogonadism (Figs. 1 and 2) . Exon 1 contained a cytosine to adenine (C to A) mutation at position 386, resulting in alanine being replaced by aspartate at residue 129 (A129D). This residue is part of the third transmembrane domain (TM3) of the receptor. Exon 3 contained a guanine to adenine (G to A) mutation at position 785, resulting in the replacement of arginine by glutamine at peptide position 262 (R262Q), in the third intracellular loop. The mutation at position 386 led to the loss of a CviJ restriction site, whereas mutation at position 785 generated a new restriction site for AluI. Segregation analyses, using restriction site enzymatic digestion plus sequencing, traced each mutant to one of the parents. The heterozygous state of each parent was confirmed by the presence of only one mutation (R262Q for the father, A129D for the mother), indicating that the patients had inherited germline mutations and were compound heterozygotes. Ϫ7 mol/L) caused a 7-fold increase in total IP production. In contrast, the A129D mutant had neither measurable binding nor any IP production.
In vivo studies
The basal hormone profiles of the parents and the three siblings are shown in Table 1 . Except for the gonadotropin deficiency in the three siblings, all the results for pituitary, thyroid, and adrenal functions were normal. Sex steroid and gonadotropin concentrations, measured 16 and 25 days after withdrawal of androgen or estrogen and progestin replacement therapy, were similar to those reported at diagnosis. The ferritin concentration was also normal. (Fig. 4,  Table 2 ). All the affected siblings had serum LH and FSH concentrations below the normal adult range. The two brothers (II1 and II2) had two and three spontaneous LH pulses during the sampling period. The LH pulses were of abnormally low amplitude (0.34 Ϯ 0.17 and 0.15 Ϯ 0.03 IU/L). The mean peak amplitudes were significantly different from that of the normogonadic father (2.39 Ϯ 0.73 IU/L). The endogenous LH secretory pattern of their sister (II3) completely lacked any apparent LH pulse. The patterns of spontaneous free ␣-subunit secretion varied with low levels in patients II1 and II3 (Fig. 5) , and significant erratic secretion in patient II2. Inhibin B levels were low or normal in the two brothers and were undetectable in their sister. (Fig. 4, Table 2 ). iv pulsatile GnRH administration (10 g/pulse), at a dose of 90 ng/kg⅐pulse (patient II1) and 115 ng/kg⅐pulse (patient II2), increased the mean LH concentrations in both patients (patient II1: from 1.16 Ϯ 0.03 to 1.58 Ϯ 0.03 IU/L; patient II2: from 0.82 Ϯ 0.01 to 2.33 Ϯ 0.08 IU/L) (P Ͻ 0.01). However, each pulse of exogenous GnRH was not associated with a pulse of LH. The mean LH peak amplitude did not increase in patient II1 (0.34 Ϯ 0.1 IU/L), whereas it did increase in patient II2 (1.11 Ϯ 0.63 IU/L). The half-lives of immunoreactive LH decreased significantly in these patients during the pulsatile GnRH administration (patient II1: before, 395; during GnRH, 230 min) (patient II2: before, 374; during GnRH, 153 min) but remained longer than the value in the normotestosteronemic father (LH half-life, 123 min). The plasma testosterone levels had not changed significantly after 40 h of pulsatile GnRH, and they remained at prepubertal values. Inhibin B concentrations did not change significantly in patient II1 and increased in patient II2 during pulsatile GnRH.
Patterns of endogenous LH and free ␣-subunit secretions
Responses to pulsatile GnRH administration
Patient II3 was given 40 h of pulsatile GnRH (10 g/pulse at 90-min intervals), for a pulse dose of 133 ng/kg; but her LH secretory profile remained apulsatile, with LH less than 0.4 IU/L (Fig. 5) . The GnRH dose was increased to 20 g/ pulse every 90 min for 24 h, which resulted in the appearance of a pulsatile LH pattern: each exogenous GnRH pulse triggered an LH response of low amplitude (0.16 Ϯ 0.01 IU/L). The estradiol levels did not increase in this patient, and they remained in the prepubertal range throughout the pulsatile GnRH administration.
All the patients showed a small, but detectable, rise in circulating FSH concentrations in response to the pulsatile GnRH administration, and their mean free ␣-subunit levels also increased. Patient II3 showed a significant increase in free ␣-subunit (234 Ϯ 8 mU/L, P Ͻ 0.01) after 40 h of 133 ng/kg⅐pulse of GnRH, whereas her LH secretory profile remained apulsatile (Fig. 5) . At the end of the pulsatile GnRH administration, the plasma LH and FSH concentrations increased significantly, after iv injection of 100 g GnRH; and the amplitudes of the responses in patients II1 and II2 were greater than before pulsatile GnRH.
Discussion
GnRH controls the reproductive function in mammals. This decapeptide is secreted into the hypophysiotropic portal circulation in a pulsatile manner and binds to specific Gprotein coupled seven-transmembrane receptors located on the gonadotrophic cells of the anterior pituitary. GnRH binding elicits the synthesis and release of free ␣-subunit and gonadotropins (LH, FSH). The GnRHR cDNA has been cloned (14, 15) , and its gene is located on the long arm of chromosome 4 between markers D4S392 and D4S409 (16) . The coding region is distributed among 3 exons separated by two large introns (17) . Rare missense mutations of the Gn-RHR gene have been recently reported in hypogonadic patients (6, 7) . In vitro studies had revealed abnormal biological activity of the mutated GnRHRs caused by decreased GnRH binding and/or reduced GnRH stimulation of IP3 production.
This report describes a family in which three of the siblings suffer from hypogonadotropic hypogonadism associated with R262Q and A129D mutations in the GnRHR gene. All the affected siblings are compound heterozygotes for these mutations, and thay have inherited a different mutation in the GnRHR gene from each parent. The disorder was transmitted as an autosomal recessive trait. This is the first description of the A129D mutation in TM3 of the GnRHR. In vitro expression studies showed that this mutation results in the complete loss of ligand binding, resulting in no GnRH-induced IP3 production. Byrne et al. (18) used site-directed mutagenesis of the GnRHR to show that the Met125 within TM3 is important for ligand binding, and that some other residues in TM3 contribute to binding. Mutations in TM3 have also been described for other G-proteincoupled receptors. An inactivating A118T mutation of the TRH receptor gene was recently described (19) , and the mutated receptor bound TRH very poorly, much like our finding. When amino-acid are aligned according to the consensus numbering scheme of Probst et al. (20) , the A 3.40(129) corresponds to V 3.40(509) for the TSH receptor and I 3.40(122) for the dopamine D2 receptor. I 3.40(122) was exposed in the binding crevice, and thus might interfere with dopamine binding (21) . Because the A129D mutation replaces a neutral residue with an acid one in TM3, it might affect electrostatic or hydrogen bond interactions with adjacent helices, or alter the molecular configuration of the receptor. It is also possible that loss of receptor function may be caused by altered transport to the cell surface. However, dot-blot hybridization of RNA confirmed that wild-type and mutant receptor genes are expressed at similar levels.
The R262Q mutation in the intracellular loop 3 of the receptor has been previously described in patients with isolated hypogonadotropic hypogonadism (6, 7) . In vitro expression studies showed that this mutated receptor binds GnRH with a normal Kd, but a 10-to 50-fold increase in the amount of GnRH agonist is needed to induce a 50% maximal increase in IP3 production. Site-directed mutagenesis of the GnRHR has also shown that the Ala residue at position 261, near R262, does not affect ligand binding but is critical for binding of the receptor to (and/or activation of) the Gprotein (22) .
Most of the patients who reported (6, 7) have the same R262Q mutation in the third intracellular loop of the receptor, but the mutation in the second allele is different. In vitro studies have shown that Q106R (6) leads to a partial loss of function, whereas Y284C (7) results in a dramatic decrease in signal transduction, and A129D abolishes GnRH-induced IP3 production in our patients. Therefore, the in vitro studies suggest that the biological activity of the mutated GnRHR is affected to a greater degree in this family than in other hypogonadic patients with mutations in the GnRHR gene.
The phenotypic spectrum of isolated hypogonadotropic hypogonadism in patients with mutations in the GnRHR gene seems to vary. The propositus of the family described by de Roux et al. (6) underwent puberty at the age of 16 yr and was referred for evaluation of incomplete hypogonadism 6 yr later, indicating that hypogonadism may be partial in subjects with mutations in the GnRHR gene. Patients II1 and II2 had microphallus and cryptorchidism, implying that gonadotropin secretion had been deficient in utero. They were referred for evaluation of lack of puberty, whereas their sister presented primary amenorrhea and impuberism. The differences in the phenotype are also obvious from the hormone profiles, with basal serum LH and FSH concentrations, which are GnRH dependent, in the upper part of the normal range in the affected patient described by de Roux et al. (6) ; whereas the basal gonadotropin concentrations were lownormal in patients reported by Layman et al. (7) , and they are below normal in the subjects we have studied. The secretory pattern of gonadotropin in our affected siblings revealed a low-normal LH pulse frequency, with a decreased amplitude in subjects II1 and II2, as reported by de Roux et al. (6) , and a complete absence of any LH pulse in their sister (II3). None of the three subjects showed any increase in basal LH interpulse frequency, which is expected in situations where the pulse generator is deprived of gonadal steroid feedback. This may be because endogenous GnRH pulses cannot trigger a rise in LH caused by the receptor impairment. These data demonstrate a wide spectrum of phenotypes and a great variation in the LH secretory pattern in isolated hypogonadotropic hypogonadism because of mutations in the GnRHR gene. This variable phenotype is obviously related to the allelic combination of the mutations in our kindred. The presence of the transmembrane domain mutation (A129D), associated with the R262Q mutation, is certainly responsible for the remarkable phenotype of this family. There is also a substantial variation in the degree of hypogonadotropic hypogonadism in patients with the same mutations in the Gn-RHR gene, because the endogenous LH secretions of the two brothers and their sister were different. This suggests that other factors influence the expression of the phenotype in such patients. Further studies on more patients are now required to address this issue.
Mutations in the receptors for hypothalamic hormones (TRH, GHRH) can lead to complete resistance (19, 23, 24) ; missense mutations in the GnRHR gene are analogous to those in the FSH or TSH receptor genes that cause variable resistance to these hormones (25) (26) (27) (28) (29) . Other patients with mutations in their GnRHR gene (6, 7), like our siblings, had increased gonadotropin concentrations after a phamacological GnRH test. To assess the functionality of the mutated receptor, we have administered iv pulsatile GnRH to the three siblings. An iv injection of 25 ng/kg GnRH replicates normal gonadotropin secretion and causes spermatogenesis or ovulation in most patients with idiopathic hypogonadotropic hypogonadism (30 -32) . Pulses of GnRH (up to 115 ng/kg⅐pulse) in patients with spontaneous LH pulse of low amplitude, increase mean circulating LH levels; and there was a significant change in mean peak amplitude in patient II2. The half-life of immunoreactive LH was shorter (but remained longer) than the value for the normotestosteronemic father. In hypogonadic patients, we might speculate that increased half-lives of immunoreactive LH resulted from altered glycosylation of LH isoforms. Plasma testosterone concentrations did not increase; they remained in the prepubertal range, suggesting the persistent secretion of LH with low biological activity (33) . Finally, baseline and GnRHstimulated inhibin B levels varied in the two brothers, as reported for GnRH-deficient men before and after short-term physiologic GnRH replacement (34) . The small effect of pulsatile GnRH on LH secretion in these patients may therefore be caused by several factors. The interval between the exogenous GnRH pulses might not have overridden the endogenous GnRH activity. The pulsatile GnRH may have been given for too short a time to induce complete gonadotropin and steroid responses, but a significant increase in testosterone levels has been observed in men with Kallmann syndrome after 2 or 3 days of physiologic GnRH replacement (4, 30) ; or there may have been some degree of resistance to GnRH in these patients. Patient II3, without any spontaneous LH pulses, had an LH secretory profile that remained apulsatile throughout the 40 h of exogenous GnRH administration at 133 ng/kg⅐pulse, whereas each exogenous 265-ng/kg pulse of GnRH given for 24 h triggered small LH pulses, demonstrating that her LH secretion did respond to the exogenous GnRH. This patient produced an early increase in free ␣-subunit levels, within 3 days of the beginning of pulsatile GnRH administration, whereas her LH secretory profile showed no apparent LH pulse, suggesting that free ␣-subunit secretion is potentially a more sensitive index of GnRH action in hypogonadic patients with mutated GnRHR gene. Similar data have been reported in women with idiopathic hypogonadotropic hypogonadism, caused by congenital GnRH deficiency, who respond to pulsatile GnRH treatment (35) . Our in vivo results thus demonstrate incomplete resistance to GnRH in these hypogonadic patients with mutations of GnRHR gene.
In conclusion, we have described a new kindred of three siblings, with isolated hypogonadotropic hypogonadism and compound heterozygote mutations in the GnRHR gene. Combined with previous reports, the phenotypic spectrum of such hypogonadism seems to vary, and this heterogeneity may be related, at least in part, to the degree of impaired biological activity of the mutated GnRHR caused by the allelic type of mutations. The transmembrane domain mutation (A129D), described here, may be responsible for the severity of this phenotype. The present study demonstrates incomplete resistance to pulsatile GnRH administration in these hypogonadic patients and suggests that they should be treated with gonadotropins to induce spermatogenesis (8) or ovulation (7), rather than with pulsatile GnRH treatment.
